FDA Inspection 1117923 — Solaris Pharma Corporation
The FDA completed an inspection of Solaris Pharma Corporation on Jan 9, 2020 in Somerset, NJ. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Jan 9, 2020
- Fiscal Year
- 2020
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Somerset, NJ (United States)
Additional Details
Bioanalytical BA/BE